Browse studies

Find your next paid study

6 recruiting studies matching your filters

NADIR Trial: A Principal Investigator-Initiated, Single-Center, Open-Label, Active-Controlled Phase 2a Study of High-Dose Nicotinamide (Vitamin B3) Supplementation in Adults With Mild to Moderate Primary Open-Angle Glaucoma (POAG)

The goal of this clinical trial is to learn whether a high-dose vitamin B3 supplement called nicotinamide can protect retinal nerve cells in adults with primar…

Glaucoma, Open-anglePrimary Open Angle Glaucoma (POAG)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of ChicagoNCT07808333

Phase 1

A Phase 1/2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension

This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hyperte…

Primary Open Angle Glaucoma (POAG)Ocular Hypertension (OHT)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07675824

Observational

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Ocular Hypertension or Open-Angle Glaucoma Patients Previously Treated With Selective Laser Trabeculoplasty (SLT)

This study looks at a new laser treatment for people with high eye pressure or a type of glaucoma called open-angle glaucoma. All patients in the study have al…

Ocular Hypertension GlaucomaPOAG

Estimated

~$10 – $1,125

Actual pay is set by the research site.

The New York Eye Surgery CenterNCT07589270

Observational

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Non-Caucasian Open Angle Glaucoma Patients

The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian pa…

Primary Open Angle Glaucoma (POAG)

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Select Eye CareNCT07147647

Phase 3

A Comparative Randomized, Investigator-Blind, Active-Controlled, Parallel-Group, Multicenter, Clinical Endpoint Study to Evaluate Efficacy and Safety of Bimatoprost Ophthalmic Solution 0.01% (YSBP) of YS Life Science Co., Ltd. (YSLS) and Lumigan® (Bimatoprost Ophthalmic Solution) 0.01% of AbbVie INC, in the Treatment of Subjects With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH).

This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. comp…

Primary Open Angle Glaucoma (POAG)Ocular Hypertension (OH)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

YS Life Science Co., Ltd.NCT07661329

Observational

Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

The goal of this study is to determine of one of three different devices to perform goniotomy to treat glaucoma at the time of cataract surgery is more or less…

Open Angle Glaucoma (OAG)Primary Open Angle Glaucoma (POAG)Secondary Open Angle Glaucoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Henry Ford Health SystemNCT07418853